Wire · opportunities
T cell therapy shows promise in treating aggressive brain cancer
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
A phase 1 clinical trial of B7-H3-targeting CAR-T cell therapy showed safety and durable tumour control in patients with treatment-resistant recurrent glioblastoma, an aggressive brain cancer with poor prognosis. The therapy demonstrated tumour reduction or stabilization for up to three years in over half the participants, including one complete remission.
This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech.
◆ ◆ The Wire takeaway
You can now focus on developing or refining CAR-T therapies targeting solid tumours like glioblastoma where options are scarce. Clinical validation of B7-H3 as a target opens a new path beyond blood cancers for T cell immunotherapy.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics